AlprostadilvsEnclomiphene

Alprostadil is synthetic prostaglandin E1 (PGE1), a 20-carbon oxygenated fatty acid derived from dihomo-gamma-linolenic acid (DGLA) through the cyclooxygenase pathway. It acts locally on penile vascular and trabecular smooth muscle through two prostaglandin E receptor subtypes: EP2 and EP4, both of which are Gs-coupled GPCRs that increase intracellular cAMP upon activation.

Elevated cAMP activates protein kinase A (PKA), which phosphorylates multiple targets in smooth muscle cells to produce relaxation. PKA phosphorylates myosin light chain kinase (MLCK), reducing its affinity for the calcium-calmodulin complex and decreasing its ability to phosphorylate myosin light chains — the final step in smooth muscle contraction. PKA also activates calcium-ATPase pumps and opens potassium channels, reducing intracellular calcium concentration. The net effect is relaxation of both the helicine arterioles (which supply blood to the corpora cavernosa) and the trabecular smooth muscle (which forms the spongy erectile tissue). As these relax, blood flows into the sinusoidal spaces of the corpora cavernosa, expanding the tissue against the tunica albuginea and compressing the subtunical veins — trapping blood and producing an erection.

The critical distinction of alprostadil's mechanism is its direct, local action independent of central sexual arousal pathways and independent of nitric oxide. PDE5 inhibitors (sildenafil, etc.) work by preventing cGMP breakdown downstream of nitric oxide release, which requires sexual arousal to generate the initial NO signal. Alprostadil generates its own second messenger (cAMP) at the injection site regardless of arousal state, which is why it produces erections reliably even in patients with neurogenic erectile dysfunction (spinal cord injury, radical prostatectomy) where the nerve-mediated NO pathway is damaged. The extremely rapid pulmonary metabolism (80% cleared in a single pass through the lungs) ensures that systemic effects are minimal when administered locally.

Enclomiphene is the trans-stereoisomer of clomiphene citrate, a selective estrogen receptor modulator (SERM). Clomiphene (Clomid) contains a roughly equal mixture of two geometric isomers: enclomiphene (trans) and zuclomiphene (cis). Enclomiphene is the pharmacologically desired isomer for testosterone elevation because it acts as a pure estrogen receptor antagonist in the hypothalamus and pituitary, while zuclomiphene has mixed agonist/antagonist activity that can cause unwanted estrogenic effects and has a much longer half-life (weeks), accumulating with chronic dosing.

Enclomiphene competitively binds to estrogen receptors (ERα) in the hypothalamus and anterior pituitary gland, blocking the binding of circulating estradiol. Normally, estradiol exerts negative feedback on the hypothalamic-pituitary axis: estradiol binding to ERα in the hypothalamus reduces GnRH pulse frequency and amplitude, while estradiol binding in the pituitary reduces gonadotroph sensitivity to GnRH. By blocking these receptors, enclomiphene removes the negative feedback signal — the hypothalamus 'perceives' low estrogen levels regardless of actual estradiol concentrations and responds by increasing GnRH pulse frequency. The pituitary, also freed from estrogen-mediated suppression, responds more robustly to each GnRH pulse, producing increased LH and FSH secretion.

Elevated LH stimulates Leydig cells in the testes to produce more testosterone (via the LHCGR/cAMP/StAR steroidogenic pathway), while elevated FSH stimulates Sertoli cells to support spermatogenesis. This is the critical advantage of enclomiphene over exogenous testosterone replacement: it raises endogenous testosterone production through the natural HPG axis while preserving (and potentially enhancing) fertility. Exogenous testosterone, by contrast, suppresses LH/FSH through negative feedback, causing testicular atrophy and often azoospermia. The 10-hour half-life of enclomiphene allows once-daily dosing, and its pure antagonist profile at ERα avoids the estrogenic side effects (hot flashes, visual disturbances, mood changes) that zuclomiphene contributes in mixed clomiphene formulations.